Enlivex Ltd. filed a Form 6-K with the SEC on October 27, 2026, disclosing that it received a delisting notification from Nasdaq on October 26, 2026, related to its failure to meet the minimum bid price requirement, and that the company intends to appeal the determination.

Key Highlights

  • Delisting Notice received: Enlivex received a delisting notification from Nasdaq's Listing Qualifications Department on October 26, 2026.
  • Bid price deficiency: The closing bid price of the company's ordinary shares did not meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) during the 30 consecutive business days prior to October 22, 2026.
  • No 180-day cure period available: Because the company effected a reverse split within the preceding 12 months, it is not entitled to the standard 180-day compliance period.
  • Appeal planned: The company plans to request an oral hearing before the Nasdaq Hearings Panel pursuant to Nasdaq Listing Rule 5815, which will stay any suspension or delisting action pending the hearing.
  • Trading continues during appeal: The ordinary shares will continue to trade on the Nasdaq Capital Market while the appeal is pending.
  • No assurance of success: According to the filing, "The Company cannot provide assurances that the Appeal will ultimately be successful and that its ordinary shares will continue to trade on the Nasdaq Capital Market following the hearing."

Enlivex Discloses Nasdaq Minimum Bid Price Deficiency and Appeal Strategy

According to the Form 6-K filed by Enlivex Ltd. (NASDAQ:ENLV) on October 27, 2026, the company disclosed that it received a formal delisting notification from the Listing Qualifications Department of The Nasdaq Stock Market Inc. on October 26, 2026. The notice stated that the closing bid price of Enlivex's ordinary shares failed to meet the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days prior to October 22, 2026.

The filing notes that, because Enlivex effected a reverse stock split within the 12 months preceding the notice, the company is not eligible for the standard 180-day grace period that Nasdaq typically grants to issuers seeking to regain compliance with the minimum bid price rule. This limits the options available to the company under the ordinary compliance framework.

In response, the company disclosed its intention to appeal the Nasdaq staff's delisting determination by filing a timely request for an oral hearing before the Nasdaq Hearings Panel, as permitted under Nasdaq Listing Rule 5815. The filing states that submitting such a request will result in a stay of any suspension or delisting action while the appeal is pending, allowing the ordinary shares to continue trading on the Nasdaq Capital Market in the interim. The company issued a press release on October 27, 2026, announcing receipt of the delisting notice, which was furnished as Exhibit 99.1 to the filing.

What Was Disclosed

Enlivex Ltd. disclosed in a Form 6-K the receipt of a Nasdaq delisting notice for failure to maintain the $1.00 minimum bid price, its ineligibility for a 180-day cure period due to a prior reverse split, and its intent to appeal through a Nasdaq Hearings Panel oral hearing.